BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 36271406)

  • 1. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Expression of Novel Immune Checkpoint Receptors on Tumor Infiltrating Lymphocytes in Patients with Locally Advanced Breast Cancer after Neoadjuvant Chemotherapy.
    Abbasov A; Aktas Cetin E; Cabioglu N; Mollavelioglu B; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen VO
    Neoplasma; 2021 Sep; 68(5):1079-1090. PubMed ID: 34097428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
    Esen F; Deniz G; Aktas EC
    Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
    Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
    Ma J; Li J; He N; Qian M; Lu Y; Wang X; Wu K
    J Transl Med; 2023 Feb; 21(1):73. PubMed ID: 36737759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
    Cabioglu N; Onder S; Oner G; Karatay H; Tukenmez M; Muslumanoglu M; İgci A; Eralp Y; Aydiner A; Saip P; Yavuz E; Ozmen V
    BMC Cancer; 2021 Apr; 21(1):357. PubMed ID: 33823818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
    Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
    Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased PD-1
    Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
    Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
    Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
    Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.
    Weimer P; Wellbrock J; Sturmheit T; Oliveira-Ferrer L; Ding Y; Menzel S; Witt M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Brauneck F
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4, PD-1, and LAG-3.
    Bagbudar S; Karanlik H; Cabioglu N; Bayram A; Ibis K; Aydin E; Yavuz E; Onder S
    Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):99-107. PubMed ID: 34608875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of immune checkpoints in T cells of esophageal cancer patients.
    Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
    Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
    Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
    Li X; Wang R; Fan P; Yao X; Qin L; Peng Y; Ma M; Asley N; Chang X; Feng Y; Hu Y; Zhang Y; Li C; Fanning G; Jones S; Verrill C; Maldonado-Perez D; Sopp P; Waugh C; Taylor S; Mcgowan S; Cerundolo V; Conlon C; McMichael A; Lu S; Wang X; Li N; Dong T
    Front Oncol; 2019; 9():1066. PubMed ID: 31709176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.